Associated Medical Professionals of New York (AMP), an affiliate of U.S. Urology Partners, is pleased to announce that it has treated the first patient in the United States under the newly approved indication for Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The historic treatment follows the U.S. Food and Drug Administration’s July 31, 2026, approval of Pluvicto in combination with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) for patients with metastatic hormone-sensitive disease.
On Monday, August 10, 2026, the AMP patient was given the first dose of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in the mHSPC space under the care of Steven E. Finkelstein, M.D., DABR, FACRO, FASTRO, Director of the Center of Advanced Radiation Excellence (CARE) and Director of Radiation Oncology Research. In 2025, Dr. Finkelstein was first in the nation to provide Pluvicto in the pre-chemotherapy space post FDA approval.
Christopher M. Pieczonka, M.D., CEO of AMP, stated, “We are incredibly proud to once again be at the forefront of bringing breakthrough cancer treatments to patients. This FDA approval represents a major advancement in prostate cancer care because it allows us to utilize precision radiopharmaceutical therapy much earlier in the disease process when patients may derive even greater benefit.”
“For men diagnosed with metastatic hormone-sensitive prostate cancer, Pluvicto offers a highly targeted treatment option that can delay cancer progression while potentially postponing the need for more intensive therapies. Being the first center in the nation to administer Pluvicto under this new indication reflects AMP’s continued commitment to innovation and providing our patients access to the latest advances in cancer care,” Dr. Pieczonka said.
The FDA approval was based on results from the Phase III PSMAddition trial of which Dr. Finkelstein served as a Principal Investigator, demonstrating that Pluvicto, when added to standard-of-care therapy consisting of ADT and an ARPI, significantly reduced the risk of disease progression or death compared with standard therapy alone. Updated trial results showed a 33% reduction in the risk of progression or death and a positive trend toward improved overall survival.
Steven Finkelstein, M.D., DABR, FACRO, FASTRO, Director of the Center of Advanced Radiation Excellence (CARE) and Director of Radiation Oncology Research at AMP, stated, “Pluvicto continues to redefine what’s possible in prostate cancer treatment. It is part of a rapidly expanding field known as theranostics, where advanced imaging and targeted therapy work hand in hand. Using PSMA PET-CT imaging, we can identify sites of prostate cancer throughout the body with remarkable accuracy. Pluvicto then delivers targeted radiation directly to those cancer cells while minimizing exposure to surrounding healthy tissues. Bringing this treatment into the hormone-sensitive setting allows us to intervene earlier and potentially improve outcomes for a much larger group of patients.”
The approval expands the use of Pluvicto across the continuum of PSMA-positive metastatic prostate cancer and nearly doubles the number of patients who may be eligible for treatment. Pluvicto is now the only PSMA-targeted radioligand therapy approved for both metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Through its Center of Advanced Radiation Excellence (CARE), AMP remains a national leader in theranostics, molecular imaging, radiopharmaceutical therapy, and precision oncology, offering patients access to some of the most advanced cancer treatments available.
About Associated Medical Professionals of New York
Associated Medical Professionals of New York, an affiliate of U.S. Urology Partners, is a leading provider of urologic, radiation oncology, imaging, and cancer care services. Through its multidisciplinary team of specialists, AMP is committed to advancing cancer care through innovation, research, and state-of-the-art treatment technologies that improve the lives of patients throughout New York and beyond.
